Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus ECX versus ECX alone in locally advanced gastric or gastroesophageal junction cancer
2008-007798-18Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in gastric cancer (GC) and esophagogastric junction cancer (2 arms), sponsored by AIO-Studien. Primary endpoint: Frequency of pT3/T4 categories after surgery. Started Feb 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2008-007798-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007798-18.